New treatments for metastatic melanoma.
作者信息
Gedye Craig, Hogg David, Butler Marcus, Joshua Anthony M
机构信息
The Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ont.
出版信息
CMAJ. 2014 Jul 8;186(10):754-60. doi: 10.1503/cmaj.130989. Epub 2014 Feb 18.
Abstract
摘要
相似文献
1
New treatments for metastatic melanoma.转移性黑色素瘤的新疗法。
CMAJ. 2014 Jul 8;186(10):754-60. doi: 10.1503/cmaj.130989. Epub 2014 Feb 18.
2
Metastatic melanoma.转移性黑色素瘤
CA Cancer J Clin. 2020 Mar;70(2):78-85. doi: 10.3322/caac.21599. Epub 2020 Feb 26.
3
[Consensus conference. Follow-up of patients surgically treated for stage I melanoma].[共识会议。I期黑色素瘤手术治疗患者的随访]
Ann Dermatol Venereol. 1995;122(5):250-8.
4
Treatment for metastatic melanoma: a new and evolving era.转移性黑色素瘤的治疗：一个全新且不断发展的时代。
Int J Clin Pract. 2015 Mar;69(3):273-80. doi: 10.1111/ijcp.12583.
5
Treatment options for limited or symptomatic metastatic melanoma.局限性或有症状转移性黑色素瘤的治疗选择。
Cancer Control. 2008 Jul;15(3):239-47. doi: 10.1177/107327480801500307.
6
[Systemic therapy of metastatic melanoma].[转移性黑色素瘤的全身治疗]
Ther Umsch. 1999 Jun;56(6):330-3. doi: 10.1024/0040-5930.56.6.330.
7
Melanoma.黑色素瘤
Cancer Chemother Biol Response Modif. 2001;19:629-38.
8
Novel Treatment of In-Transit Metastatic Melanoma With Shave Excision, Electrodesiccation and Curettage, and Topical Imiquimod 5% Cream. shave 切除术、电干燥术和刮除术联合咪喹莫特 5%乳膏治疗转移性黑素瘤的新方法。
J Drugs Dermatol. 2021 May 1;20(5):555-557. doi: 10.36849/JDD.5675.
9
Surgical treatment options for stage IV melanoma.IV 期黑色素瘤的手术治疗选择。
Surg Clin North Am. 2014 Oct;94(5):1075-89, ix. doi: 10.1016/j.suc.2014.07.009. Epub 2014 Aug 2.
10
Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part II.前哨淋巴结活检对已发生淋巴结转移的原发性皮肤黑色素瘤患者无益处：基于全面、批判性分析的论断：第二部分。
Am J Dermatopathol. 2003 Dec;25(6):473-84. doi: 10.1097/00000372-200312000-00004.
引用本文的文献
1
A rare case of brain metastatic malignant melanoma coexisting with black colored dura mater: Management in low-resource setting.一例罕见的脑转移恶性黑色素瘤合并黑色硬脑膜病例：资源匮乏地区的处理
Surg Neurol Int. 2025 Jan 24;16:21. doi: 10.25259/SNI_535_2024. eCollection 2025.
2
Assessing the Educational and Supportive Care Needs of Canadian Metastatic Melanoma Patients and Survivors Attending an Outpatient Clinic.评估在门诊就诊的加拿大转移性黑色素瘤患者及幸存者的教育和支持性护理需求。
J Patient Exp. 2021 Jul 23;8:23743735211033126. doi: 10.1177/23743735211033126. eCollection 2021.
3
Psychosocial distress in patients with cutaneous melanoma: validation of the Skin Cancer Index (SCI).皮肤黑色素瘤患者的心理社会困扰：皮肤癌指数（SCI）的验证。
Support Care Cancer. 2021 Feb;29(2):1005-1014. doi: 10.1007/s00520-020-05568-w. Epub 2020 Jun 19.
4
Advances in Carbon Nanotubes for Malignant Melanoma: A Chance for Treatment.用于恶性黑素瘤的碳纳米管的进展：治疗的机会。
Mol Diagn Ther. 2018 Dec;22(6):703-715. doi: 10.1007/s40291-018-0363-7.
5
High frequency ultrasound with color Doppler in dermatology.高频超声结合彩色多普勒在皮肤科的应用
An Bras Dermatol. 2016 May-Jun;91(3):262-73. doi: 10.1590/abd1806-4841.20164446.
6
Current and Evolving Methods to Visualize Biological Data in Cancer Research.癌症研究中可视化生物数据的当前及不断发展的方法
J Natl Cancer Inst. 2016 May 31;108(8). doi: 10.1093/jnci/djw031. Print 2016 Aug.
7
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.伊匹单抗治疗转移性黑色素瘤的真实世界疗效、毒性及临床管理
Oncol Lett. 2016 Feb;11(2):1581-1585. doi: 10.3892/ol.2015.4069. Epub 2015 Dec 31.
本文引用的文献
1
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
2
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.拉罗替尼（anti-PD-1）治疗黑色素瘤的安全性和肿瘤应答。
N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.
3
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.转移性黑色素瘤患者肿瘤浸润淋巴细胞的过继转移：既往免疫治疗失败后的意向治疗分析和疗效。
Clin Cancer Res. 2013 Sep 1;19(17):4792-800. doi: 10.1158/1078-0432.CCR-13-0380. Epub 2013 May 20.
4
Hepatotoxicity with combination of vemurafenib and ipilimumab.维莫非尼与伊匹木单抗联合使用时的肝毒性。
N Engl J Med. 2013 Apr 4;368(14):1365-6. doi: 10.1056/NEJMc1302338.
5
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.嵌合抗原受体修饰的 T 细胞治疗急性淋巴细胞白血病。
N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.
6
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.在初始疾病控制后进展的预处理晚期黑色素瘤患者中，用伊匹单抗进行再治疗的疗效和安全性。
Clin Cancer Res. 2013 Apr 15;19(8):2232-9. doi: 10.1158/1078-0432.CCR-12-3080. Epub 2013 Feb 26.
7
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.BRAF V600 突变型黑色素瘤的联合 BRAF 和 MEK 抑制治疗。
N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
8
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.广泛存在生长因子驱动的抗癌症激酶抑制剂耐药性的潜力。
Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249.
9
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
10
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
Zotero 插件